Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026)

Aura Biosciences has reported Cash from Financing Activities for 7 years, with the latest figure at $300000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 212.5% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $77.4 million (up 5279.62% YoY), and the FY2025 full-year result was $77.2 million, up 4737.3% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $300000.0, down from $2.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $95.2 million in Q4 2022, with the low at $17000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $16.0 million across 5 years, with a median of $543000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.98% — and 2025, when it surged 84151.81%.
• Aura Biosciences' Cash from Financing Activities stood at $95.2 million in 2022, then declined by 2.33% to $93.0 million in 2023, then plunged by 99.42% to $543000.0 in 2024, then soared by 409.58% to $2.8 million in 2025, then tumbled by 89.16% to $300000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $300000.0 (Q1 2026), $2.8 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.